Welcome to our dedicated page for Foghorn Therapeutics news (Ticker: FHTX), a resource for investors and traders seeking the latest updates and insights on Foghorn Therapeutics stock.
Foghorn Therapeutics Inc., founded in 2015 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and developing a new class of medicines. These medicines target genetically determined dependencies within the chromatin regulatory system using Foghorn's proprietary Gene Traffic Control® Platform. This platform provides an integrated, mechanistic understanding of how various components of the chromatin regulatory system interact, allowing the identification, validation, and potential drugging of targets within the system.
The company's lead programs include FHD-286 and FHD-609. FHD-286 is a small-molecule enzymatic inhibitor of BRG1 and BRM, targeting acute myeloid leukemia (AML) and uveal melanoma. FHD-609 is a protein degrader of BRD9 aimed at treating synovial sarcoma. Additionally, Foghorn is developing preclinical and discovery programs such as selective BRM targeting non-small-cell lung cancer and selective ARID1B modulators for bladder, ovarian, and endometrial cancer.
Foghorn has established a collaboration with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target. The company's financial stability is reflected in its cash and equivalents of approximately $259.9 million as of September 30, 2023, which supports its robust pipeline and strategic objectives for 2024 and beyond.
Recent Achievements and Current Projects:
- Initiated a Phase 1 combination study of FHD-286 in AML with data expected in the second half of 2024.
- Progress with the selective BRM inhibitor FHD-909, with an IND planned for the second quarter of 2024, primarily targeting non-small cell lung cancer.
- Presented preclinical data showcasing selective CBP and EP300 degrader programs, demonstrating significant tumor growth inhibition without associated hematopoietic toxicity.
- Announced multiple strategic milestones, including financial updates and corporate outlooks, reflecting continued progress across various therapeutic programs.
The company remains committed to advancing its preclinical and clinical programs, supported by collaborations and financial investments, with the goal of developing novel medicines that can transform the lives of patients with serious diseases.
Foghorn Therapeutics (Nasdaq: FHTX) announced that Steven Bellon, Ph.D., Senior Vice President of Drug Discovery, will speak at the 2021 Wedbush PacGrow Healthcare Virtual Conference on August 11, 2021, at 10:20 a.m. ET. The panel titled 'Bullseye – Targeted Oncology Part 2' will discuss advancements in oncology. Additionally, Foghorn's management will conduct investor meetings during the event. A live webcast of the panel can be accessed in the Investors section of their website, www.foghorntx.com.
Foghorn Therapeutics (Nasdaq: FHTX) announces participation in the William Blair Biotech Focus Conference 2021 with CEO Adrian Gottschalk on July 15 at 9:00 a.m. ET. The conference will focus on next-generation small molecules in oncology. A live webcast of the panel can be accessed through the company’s website under the ‘Events & Presentations’ section. Foghorn is dedicated to developing a novel class of medicines targeting genetically determined dependencies in the chromatin regulatory system, with ongoing projects in oncology.
Foghorn Therapeutics Inc. (Nasdaq: FHTX) will host a research and development webinar on June 15, 2021, from 9:00 AM to 11:00 AM EDT. Key presentations will be made by management and experts from notable institutions, including Howard A. Burris III and Eytan Stein. The event will cover the significance of the chromatin regulatory system in gene expression and its application in precision oncology, featuring Foghorn's Gene Traffic Control platform. A live Q&A session will follow the presentations. Registration is available online.
Foghorn Therapeutics Inc. (Nasdaq: FHTX) announced that CEO Adrian Gottschalk will present at two upcoming investor conferences. The Jefferies Virtual Healthcare Conference is scheduled for June 1, 2021, at 10:00 am ET, featuring a presentation and one-on-one meetings. The Goldman Sachs 42nd Annual Healthcare Conference will take place on June 8, 2021, at 8:00 am ET, including a fireside chat and one-on-one meetings. Interested investors can access the live webcasts through the company’s website under the “Events & Presentations” section.
Foghorn Therapeutics (Nasdaq: FHTX) announced the first patient has been dosed in a first-in-human clinical trial of FHD-286, targeting metastatic uveal melanoma (mUM) and relapsed/refractory acute myelogenous leukemia (AML). This marks a significant milestone as FHD-286 is the first clinical candidate from Foghorn's diverse pipeline, designed to inhibit the chromatin regulatory system. Both trials are open-label and focus on safety and efficacy, highlighting Foghorn's innovative approach to treating cancers with limited options.
Foghorn Therapeutics (Nasdaq: FHTX) received IND clearance for FHD-609, a targeted protein degrader for synovial sarcoma. This marks a significant milestone alongside advancement in their therapeutic pipeline aimed at the chromatin regulatory system. FHD-609 is Foghorn's second drug to enter clinical trials, with initial data expected in early 2022. The company also received IND clearance for FHD-286, targeting relapsed AML and metastatic uveal melanoma. Financially, Foghorn reported cash and equivalents of $160.9 million as of March 31, 2021, down from $185.8 million at year-end 2020.
Foghorn Therapeutics (FHTX) announced the appointment of Ian Smith to its Board of Directors, effective April 27, 2021. Smith, a seasoned biotechnology leader, has been advising Foghorn since 2020 on business development and financing strategies. CEO Adrian Gottschalk expressed optimism over Smith's experience in capital formation and business growth, which is expected to enhance the company’s focus on chromatin regulatory systems. Smith brings a wealth of experience from positions at Viacyte and Vertex Pharmaceuticals, which may contribute to Foghorn's potential therapeutic breakthroughs in oncology.
Foghorn Therapeutics Inc. (Nasdaq: FHTX) issued a corporate update, revealing that the company has received IND clearances for its therapeutic candidate FHD-286. Initial clinical studies for FHD-286 in relapsed/refractory AML and metastatic uveal melanoma are set to begin, with data expected by year-end 2021. Additionally, FHD-609’s IND submission is on track for Q2 2021. The company successfully raised approximately $135.2 million through an IPO and reported cash holdings of $185.8 million as of December 31, 2020, up significantly from $15 million in the previous year.
Foghorn Therapeutics (Nasdaq: FHTX) announced its participation in the AACR Annual Meeting 2021, occurring virtually from April 10-15. The company will present a poster titled ‘Discovery of novel BAF inhibitors for the treatment of transcription factor-driven cancers’, available on demand from 8:30 AM on April 10. Additionally, Foghorn will chair a panel on next-generation epigenetic drugs on April 14. Preclinical data highlight the potential of BAF ATPase inhibition, particularly for uveal melanoma, paving the way for future human studies.
Foghorn Therapeutics (Nasdaq: FHTX) announced its participation in the AACR Annual Meeting 2021, scheduled for April 10-15. The company will present a poster titled Discovery of novel BAF inhibitors for the treatment of transcription factor-driven cancers, available on demand from 8:30 AM on April 10. Furthermore, Foghorn will chair a panel discussion on Next-Generation Epigenetic Drugs on April 14, featuring an accompanying presentation on targeting the BAF complex in cancer. These initiatives align with Foghorn's focus on developing medicines targeting chromatin regulatory systems.
FAQ
What is the current stock price of Foghorn Therapeutics (FHTX)?
What is the market cap of Foghorn Therapeutics (FHTX)?
What is Foghorn Therapeutics Inc. focused on?
What are the main products under development by Foghorn Therapeutics?
What is the Gene Traffic Control® Platform?
What are some of the recent achievements of Foghorn Therapeutics?
What is Foghorn Therapeutics' financial condition?
Who are Foghorn Therapeutics' collaborators?
When was Foghorn Therapeutics founded?
Where is Foghorn Therapeutics headquartered?
What are Foghorn Therapeutics' key areas of research?
What is the strategic outlook for Foghorn Therapeutics in 2024?
